AcquisitionsApr 27, 2026, 06:12 AM
OGN to be Acquired by Sun Pharma for $14.00/share, EV $11.75B
AI Summary
Organon & Co. (OGN) announced a definitive agreement to be acquired by Sun Pharmaceutical Industries Limited for US$14.00 per share in an all-cash transaction, valuing Organon at an enterprise value of US$11.75 billion. The acquisition is expected to close in early 2027, subject to regulatory and stockholder approvals. This deal aims to strengthen Sun Pharma's Innovative Medicines and Established Brands businesses, enabling its entry into biosimilars as a top-10 global player and creating a combined entity with US$12.4 billion in revenue.
Key Highlights
- Sun Pharma will acquire Organon & Co. (OGN) for US$14.00 per share in an all-cash transaction.
- The deal values Organon at an enterprise value of US$11.75 billion.
- The transaction is expected to close in early 2027, subject to regulatory and stockholder approvals.
- The combined company is projected to achieve US$12.4 billion in revenue.
- Sun Pharma will become a top 3 company in global Women’s Health and the 7th largest global biosimilar player.
- Organon reported US$6.2 billion in revenue and US$1.9 billion in Adjusted EBITDA for the year ended December 31, 2025.